Diarylquinolines, synthesis pathways and quantitative structure–activity relationship studies leading to the discovery of TMC207

The challenge of new drug discovery for tuberculosis

(2011) Anil Koul et al.   NATURE

Global tuberculosis drug development pipeline: the need and the reality

(2010) Zhenkun Ma et al.   LANCET

The HIV-associated tuberculosis epidemic—when will we act?

(2010) Anthony D Harries et al.   LANCET

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

(2009) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

New anti-tuberculosis agents amongst known drugs

(2009) Kathryn E.A. Lougheed et al.   TUBERCULOSIS

Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue

(2008) A. C. Haagsma et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis

(2008) Anil Koul et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)

(2008) Andrew J. Nunn et al.   TUBERCULOSIS